Skip to main content scroll back to top of page

Chimerix is now part of Jazz Pharmaceuticals. Learn more at www.jazzpharma.com

Chimerix Logo

Utility Navigation

Chimerix Logo

Primary Navigation

Close Menu
  • Patients
    • Expanded Access
    • Clinical Trials
  • About Imipridones
    • About Impipridones
      About ImpipridonesImipridones

      Oncology: Imipridones

      • ONC201 dordaviprone for gliomas
      • ONC206 for central nervous system tumors
      • ONC212 IND-enabling studies
      PublicationsNeuro Oncology Publications2024 SNO Annual Conference
  • Careers
  • Contact

Chimerix is now part of Jazz Pharmaceuticals

About Jazz Pharmaceuticals

Expanded Access

For more information about Expanded Access

For Healthcare professionals only

If you are interested in meeting with the Chimerix team, please feel free to reach out to us at [email protected] to coordinate an in-person meeting.

We look forward to connecting with you and answering any questions you may have about our programs.


Chimerix Logo
  • Chimerix on LinkedIn
  • Chimerix on Twitter

Legal Menu

  • Privacy Notice
  • Cookie Notice 
  • Terms & Conditions of Use
  • Forward-Looking Statements
  • Community Guidelines

© 2025 Copyright Chimerix. All rights reserved.

We are pleased to share that a new treatment for H3 K27M-mutant diffuse midline glioma received FDA accelerated approval. This milestone is a meaningful advancement in the treatment of an ultra-rare and aggressive brain tumor, which primarily affects children and young adults.

Select Jazz to learn more about our latest news in H3 K27M-mutant diffuse midline glioma.
Select continue to proceed to the Chimerix website

Jazz